Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

The primary objective of the study is to evaluate efficacy of entospletinib in participants
with relapsed or refractory hematologic malignancies. Participants with the following
relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or
refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large
B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas
(iNHL; including lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia [LPL/WM], small
lymphocytic lymphoma [SLL], or marginal zone lymphoma [MZL]).

Treatment Sites in Georgia